Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 7%
Hold 79%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. is positioned favorably in the biotechnology sector due to its collaboration with Gilead, which enhances its manufacturing capabilities and patient support systems for its CAR-T therapy, anito-cel. The company's promising pipeline reflects strong clinical data, particularly in multiple myeloma, with expectations of a significant market entry projected by the end of 2026, potentially resulting in peak global sales of $7 billion. Successful execution by Arcellx's management in developing innovative therapies underscores the value proposition for shareholders, especially as anito-cel's clinical profile continues to show durability comparable to existing therapies in the market.

Bears say

The financial analysis of Arcellx Inc. reveals a concerning outlook due to a series of significant risks affecting its valuation. The proposed acquisition by Gilead Sciences for an implied equity value of $7.8 billion introduces uncertainty, particularly if Arcellx fails to develop additional successful clinical candidates from its D-Domain CAR-T and ARC-SparX platforms. Furthermore, multiple risk factors, including commercial competition, potential regulatory challenges, and concerns about product efficacy, could adversely impact Arcellx's stock performance and overall market position.

Arcellx (ACLX) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 7% recommend Buy, 79% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Hold based on their latest research and market trends.

According to 14 analysts, Arcellx (ACLX) has a Hold consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.